(MedPage Today) — The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years and older with a confirmed mutation in the survival motor neuron…
Source link : https://www.medpagetoday.com/neurology/generalneurology/118708
Author :
Publish date : 2025-11-25 17:34:00
Copyright for syndicated content belongs to the linked Source.
